| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2009 | US20090029957 8-beta-substituted estratrienes as selectively active estrogens |
| 01/29/2009 | US20090029956 Substance mixture |
| 01/29/2009 | US20090029955 Pyridothienopyrimidine Derivatives |
| 01/29/2009 | US20090029954 Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
| 01/29/2009 | US20090029953 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter |
| 01/29/2009 | US20090029952 Unique combination of acetylsalicylic acid, ethylenediamine dihydroiodide (eddi), and buffer for use in animal drinking water |
| 01/29/2009 | US20090029951 Antihypoxia agent; monocalcium tetrasodium salt of inositol tripyrophosphate; cancer, Alzheimer's |
| 01/29/2009 | US20090029950 Composition for Reducing the Exudation of Serum Proteins |
| 01/29/2009 | US20090029949 GPCR Ligands Identified by Computational Modeling |
| 01/29/2009 | US20090029947 Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| 01/29/2009 | US20090029946 Aqueous oral solution of bisphosphonic acid |
| 01/29/2009 | US20090029945 Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators |
| 01/29/2009 | US20090029944 Methods for adding fatty acids to agents in aqueous solution to improve bioavailability |
| 01/29/2009 | US20090029943 Glucosamine and Derivatives Thereof Useful as TG Inhibitors |
| 01/29/2009 | US20090029942 Administration of copper to an animal |
| 01/29/2009 | US20090029941 Methods for cell mobilization using in vivo treatment with hyaluronan (ha) |
| 01/29/2009 | US20090029940 Plymorphic form of inulin and uses thereof |
| 01/29/2009 | US20090029939 Pre-organized tricyclic integrase inhibitor compounds |
| 01/29/2009 | US20090029938 Phosphodiesterase inhibitor for treatment and prevention of asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis |
| 01/29/2009 | US20090029937 Biodegradable cationic polymer gene transfer compositions and methods of use |
| 01/29/2009 | US20090029936 Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| 01/29/2009 | US20090029935 Centrosomal proteins and secretion |
| 01/29/2009 | US20090029934 RNA interference in respiratory epithelial cells |
| 01/29/2009 | US20090029933 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1 |
| 01/29/2009 | US20090029932 Identification and use of miRNAs for differentiating myeloid leukemia cells |
| 01/29/2009 | US20090029931 Topical administrations of antisense compounds to vla-4 for the treatment of respiratory conditions |
| 01/29/2009 | US20090029930 Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter |
| 01/29/2009 | US20090029929 Decoy Nucleic Acid to Synoviolin Gene Promoter |
| 01/29/2009 | US20090029928 Peeling process and composition |
| 01/29/2009 | US20090029927 Compounds having inhibitory activity against sodium-dependent glucose transporter |
| 01/29/2009 | US20090029922 Use of S1P receptor agonists in heart diseases |
| 01/29/2009 | US20090029916 Fibroblast Growth Factor-14 |
| 01/29/2009 | US20090029905 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 01/29/2009 | US20090029904 Compositions and methods for treatment of insulin-resistance diseases |
| 01/29/2009 | US20090029903 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors |
| 01/29/2009 | US20090029901 Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations |
| 01/29/2009 | US20090029856 Hinokitiol As A Plant Pesticide |
| 01/29/2009 | US20090029415 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/29/2009 | US20090029400 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/29/2009 | US20090029361 Growth differentiation factor-7 |
| 01/29/2009 | US20090028974 Use of Botulinum Toxin Therapy for Treatment of Recalcitrant Voiding Dysfunction |
| 01/29/2009 | US20090028970 Antiallergic composition |
| 01/29/2009 | US20090028969 Compostion for treating skin |
| 01/29/2009 | US20090028968 Pharmaceutical Platform Technology for the Development of Natural Products |
| 01/29/2009 | US20090028966 Methods for Introducing Reactive Secondary Amines Pendant to Polymers Backbones that are Useful for Diazeniumdiolation |
| 01/29/2009 | US20090028964 container for suppositories comprises a base having a substantially planar surface with a plurality of surface openings; suppository mixture is spread across surface such that mixture falls through openings dispersed across surface and into hollow members |
| 01/29/2009 | US20090028963 Polyphenol Coxib Combinations and Methods |
| 01/29/2009 | US20090028962 Methods and Compositions for Enhancing Iron Absorption |
| 01/29/2009 | US20090028959 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
| 01/29/2009 | US20090028958 Cosmetic Makeup and/or Care Process |
| 01/29/2009 | US20090028953 Method of treatment using microparticulate biomaterial composition |
| 01/29/2009 | US20090028952 Hydroxy sulfonate of quinone compounds and their uses |
| 01/29/2009 | US20090028948 Nanoparticle composition and methods of synthesis thereof |
| 01/29/2009 | US20090028944 Pharmaceutical compositions comprising mesalamine |
| 01/29/2009 | US20090028943 Pharmaceutical compositions |
| 01/29/2009 | US20090028942 Sustained release compositions of alfuzosin |
| 01/29/2009 | US20090028941 Pulsatile gastric retentive dosage forms |
| 01/29/2009 | US20090028940 Pharmaceutical compositions of rifaximin |
| 01/29/2009 | US20090028939 Solid Preparation |
| 01/29/2009 | US20090028937 Tablet comprising ornithine hydrochloride |
| 01/29/2009 | US20090028936 Tablets containing enrofloxacin and flavouring agents and/or flavours |
| 01/29/2009 | US20090028935 Carvedilol forms, compositions, and methods of preparation thereof |
| 01/29/2009 | US20090028934 Granular, gastro-resistant product based on niacin or derivates thereof and process for the production of such a product |
| 01/29/2009 | US20090028933 Compositions and methods for treating lymphoma |
| 01/29/2009 | US20090028931 Liposomal compositions for parenteral delivery of agents |
| 01/29/2009 | US20090028930 Bruise amelioration composition and method of use |
| 01/29/2009 | US20090028929 Transdermal Patch |
| 01/29/2009 | US20090028926 Method and mixture for in vivo photochemical cross-linking of collagen |
| 01/29/2009 | US20090028925 Novel Phosphinic Acid-Containing Thyromimetics |
| 01/29/2009 | US20090028920 Urological devices incorporating collagen inhibitors |
| 01/29/2009 | US20090028918 Gynecological pharmaceutics- containing microspherical vascular suppository of sodium alginate and its preparation method |
| 01/29/2009 | US20090028916 Loaded Microspheres |
| 01/29/2009 | US20090028914 Medical devices incorporating collagen inhibitors |
| 01/29/2009 | US20090028910 Methods for Fabrication Isolated Micro-and Nano-Structures Using Soft or Imprint Lithography |
| 01/29/2009 | US20090028904 Novel cochleate formulations |
| 01/29/2009 | US20090028895 Methods and compositions for reducing facial lines and wrinkles |
| 01/29/2009 | US20090028887 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/29/2009 | US20090028878 Novel methods of cancer diagnosis and therapy targeted against a cancer stem line |
| 01/29/2009 | US20090028875 Use of gilz protein expressed in dendritic cells to modulate an antigen-specific immune response |
| 01/29/2009 | US20090028873 Substituted cyclohexanols |
| 01/29/2009 | US20090028871 Novel use of ligands specific to fex-2 polypeptide |
| 01/29/2009 | US20090028868 Anti-cancer pharmaceutical compositions and methods for treating patients with cancer |
| 01/29/2009 | US20090028867 Antagonists Specific For Denatured Collagen And Methods Of Using Same |
| 01/29/2009 | US20090028866 USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE |
| 01/29/2009 | US20090028864 L-amino acid oxidase with cytotoxic activity from aplysia functata |
| 01/29/2009 | US20090028863 Markers for diagnosis of cancer and its use |
| 01/29/2009 | US20090028862 Emmprin antagonists and uses thereof |
| 01/29/2009 | US20090028861 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 01/29/2009 | US20090028858 Substituted quinoline derivatives |
| 01/29/2009 | US20090028855 Inhibitors of akt/pkb with anti-tumor activity |
| 01/29/2009 | US20090028851 Novel Antibodies Directed to the Mammalian Eag1 Ion Channel Protein |
| 01/29/2009 | US20090028850 Prolongation of survival of an allograft by inhibiting complement activity |
| 01/29/2009 | US20090028845 obtaining a sample from the subject's frontal cortex, analyzing the level of expression of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene, wherein reduced levels of expression of UCH-L1 gene compared to controls is diagnostic of DLB; Alzheimer's Disease and Parkinson's disease |
| 01/29/2009 | US20090028844 Galnts as modifiers of the igfr pathway and methods of use |
| 01/29/2009 | US20090028843 IgA allelic variants |
| 01/29/2009 | US20090028842 Dekkera/Brettanomyces Cytosine Deaminases And Their Use |
| 01/29/2009 | US20090028829 Fusion proteins for the treatment of CNS |
| 01/29/2009 | US20090028824 Systems and methods for delivering drugs |
| 01/29/2009 | US20090028823 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| 01/29/2009 | US20090028821 Prodrugs of cc-a1065 analogs |